[PDF][PDF] Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
I Krop, T Demuth, T Guthrie, PY Wen… - Journal of clinical …, 2012 - researchgate.net
Journal of clinical oncology, 2012•researchgate.net
Purpose Aberrant Notch signaling has been implicated in the pathogenesis of many human
cancers. MK-0752 is a potent, oral inhibitor of-secretase, an enzyme required for Notch
pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs),
pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of
MK-0752.
cancers. MK-0752 is a potent, oral inhibitor of-secretase, an enzyme required for Notch
pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs),
pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of
MK-0752.
Purpose
Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of-secretase, an enzyme required for Notch pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of MK-0752.
researchgate.net